Peptides vs Growth Hormone
How growth hormone itself differs from growth-hormone-releasing peptides, what each is approved for, and what trials in healthy people have and have not shown.
Content last updated . This page has not been medically reviewed.
Why this comparison matters
"Growth hormone peptides" is a marketing phrase. It can mean growth hormone itself, a molecule that prompts the body to release it, or an unrelated product. This page separates them. It is information only. It does not tell anyone which compound to use.How we label evidence
We use plain labels: approved medicine (with the regulator and use), established, promising but limited, mixed, insufficient evidence, preclinical (cells or animals only), no good evidence of benefit, evidence of harm, and marketing claim. "Proper evidence not found" means we looked and found nothing usable.Growth hormone itself
Somatropin is recombinant human growth hormone. In the Norditropin label, it is a protein of 191 amino acids whose sequence is identical to pituitary growth hormone. [1] The National Human Genome Research Institute puts typical peptides at 2 to 50 amino acids, so this is a protein-sized molecule, though the cutoff is a convention. [2] See peptides vs proteins.Evidence label: approved medicine in the United States (FDA label read 2026-10-22). Norditropin is indicated for growth failure in children from several causes and for replacing growth hormone in adults with growth hormone deficiency. [1] The label states it is not indicated for non-GH deficient adults. [1]
Growth-hormone-releasing peptides
These molecules act upstream. Tesamorelin is a synthetic analog of growth hormone-releasing factor. [3] The label explains that this hypothalamic peptide prompts the pituitary to release the body's own growth hormone. [3] Evidence label: approved medicine in the United States for reducing excess abdominal fat in HIV-infected adults with lipodystrophy. [3] The label says it increases IGF-1, that the effects of prolonged IGF-1 elevation are unknown, and that IGF-1 should be monitored. [3]Other names, such as CJC-1295, ipamorelin and GHRP-2, appear in FDA's list of compounding substances with safety concerns. The FDA reports serious adverse events associated with CJC-1295 and limited clinical data. [4] For ipamorelin it cites a published study with serious adverse events including death when given intravenously for gastric motility. [4] It notes immune-reaction risks from aggregation and impurities for GHRP-2. [4] These are U.S. compounding statements, not approvals. See growth-hormone-releasing peptides.
What trials of growth hormone in healthy people found
| Question | Review | What it found | Where it stops |
|---|---|---|---|
| Healthy older adults | 18 study populations, 220 participants who received GH [5] | Fat mass down, lean mass up; more edema, joint pain, carpal tunnel syndrome and gynecomastia; somewhat more diabetes onset [5] | Most studies small; some outcomes not measured. Authors did not recommend GH as an anti-aging therapy [5] |
| Young fit adults and performance | 27 study samples, 303 participants [6] | Lean mass up; strength and exercise capacity did not seem to improve; more edema and fatigue [6] | Few studies measured athletic performance; study regimens may not match real use [6] |
| Healthy young adults, newer meta-analysis | 11 placebo-controlled trials, 254 participants [7] | Body composition changed; muscle strength and aerobic capacity did not rise [7] | Trials lasted weeks to months [7] |
Evidence label for these uses: no good evidence of benefit for performance, and evidence of more adverse events.
What is not known for releasing peptides
For the unapproved releasing peptides, Proper evidence not found in the sources read for this page: we did not find controlled trials showing body-composition or performance benefit in healthy people. We checked the FDA page and the reviews above. That does not prove none exist. Also, a higher GH or IGF-1 reading is a biomarker, not a health outcome, and the Egrifta label itself says the effects of prolonged IGF-1 elevation are unknown. [3]No universal winner
Growth hormone and releasing peptides are different tools with different regulators' labels and different risks. Neither is shown to be a safe anti-aging or sport enhancer. Anyone with a growth hormone question can talk with an endocrinologist; see talking with a health professional.Frequently asked questions
Is growth hormone a peptide?
It is usually called a protein hormone because it has 191 amino acids. [1] Sources draw the peptide/protein line differently. [2]
Do growth hormone peptides raise growth hormone?
Tesamorelin, an approved analog, is described as stimulating the pituitary to release endogenous GH. [3] Whether other marketed products do the same, in what amount and for whom, depends on each compound and its evidence.
Does growth hormone improve athletic performance?
Systematic reviews found more lean mass but no clear gain in strength or exercise capacity, and more side effects. [6][7]
Is growth hormone approved for anti-aging?
The 2007 review noted that FDA had not approved it for that purpose. [5] The current Norditropin label lists no such use. [1]
References
- DailyMed, Norditropin (somatropin) injection, prescribing information, Novo Nordisk. Read 2026-10-22.
- National Human Genome Research Institute, Genetics Glossary: Peptide. Read 2026-10-22.
- DailyMed, Egrifta SV (tesamorelin) prescribing information, Theratechnologies. Read 2026-10-22.
- U.S. Food and Drug Administration, Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks (content current as of 04/22/2026). Read 2026-10-22.
- Systematic review: the safety and efficacy of growth hormone in the healthy elderly. Ann Intern Med 2007. Abstract read 2026-10-22.
- Systematic review: the effects of growth hormone on athletic performance. Ann Intern Med 2008. Abstract read 2026-10-22.
- Impact of GH administration on athletic performance in healthy young adults: a systematic review and meta-analysis of placebo-controlled trials. Growth Horm IGF Res 2017. Abstract read 2026-10-22.